Concepedia

Author

Serafín Morales

Hospital Universitari Arnau de VilanovaORCID

Also Known As

A. Lorenzo, Ana Agreda, C. Jara, E Lafoz, Estela Vega Alonso, Morales, Samuel, S Morales, S Morales Murillo, S. M. Murillo, S. Morales

339

Publications

6.6K

Citations

30

H-Index

47

Concepts

All Affiliations

Hospital Universitari Arnau de VilanovaHospital Arnau de VilanovaVall d'Hebron Institute of OncologyVall d'Hebron Hospital UniversitariHospital Clínico Universitario de Valencia
SM

About

Serafín Morales is an author at Hospital Universitari Arnau de Vilanova specializing in medicine, breast cancer, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

19

34

3.2K

2

Health Sciences

10

11

1.6K

3

Immunology

2

2

35

4

Nursing

1

1

30

5

Cell Biology

1

1

39

Serafín Morales

×

71

Publications

6.1K

Citations

30

H-Index

YearCitations

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim,

The Lancet Oncology

2020

854

Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

Nicholas C. Turner, Mafalda Oliveira, Sacha J. Howell,

New England Journal of Medicine

2023

600

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen,

The Lancet Oncology

2017

578

Phase II Study of Efficacy, Safety, and Pharmacokinetics of Trastuzumab Monotherapy Administered on a 3-Weekly Schedule

José Baselga, Xavier Carbonell, Noel-Jaime Castañeda-Soto,

Journal of Clinical Oncology

2005

425

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber,

Annals of Oncology

2022

404

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial

Antonio Llombart‐Cussac, Javier Cortés, Laia Paré,

The Lancet Oncology

2017

329

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial

Ian E. Krop, Ingrid A. Mayer, Vinod Ganju,

The Lancet Oncology

2016

288

Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial

Arlene Chan, Beverly Moy, Janine Mansi,

Clinical Breast Cancer

2020

211

Cisplatin Plus Gemcitabine Versus a Cisplatin-Based Triplet Versus Nonplatinum Sequential Doublets in Advanced Non–Small-Cell Lung Cancer: A Spanish Lung Cancer Group Phase III Randomized Trial

V. Alberola, Carlos Camps, Mariano Provencio,

Journal of Clinical Oncology

2003

192

HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

Aleix Prat, Tomás Pascual, Carmine De Angelis,

JNCI Journal of the National Cancer Institute

2019

163

Page 1